<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360918</url>
  </required_header>
  <id_info>
    <org_study_id>NL35192.044.11</org_study_id>
    <nct_id>NCT01360918</nct_id>
  </id_info>
  <brief_title>Concomitant Epicardial Pulmonary Vein Isolation in Patients With Atrial Fibrillation Undergoing Elective Cardiac Surgery</brief_title>
  <acronym>CONTROL-AF</acronym>
  <official_title>Concomitant Epicardial Pulmonary Vein Isolation in Patients With Atrial Fibrillation Undergoing Elective Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medisch Spectrum Twente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardio Research Enschede BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medisch Spectrum Twente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies demonstrated that radiofrequency isolation of the pulmonary veins (PVI) is a
      superior alternative to antiarrhythmic drug therapy in patients with symptomatical paroxysmal
      atrial fibrillation (AF). A substantial proportion of patients undergoing elective cardiac
      surgery also suffer from atrial fibrillation. No evidence exists if epicardial PVI is
      beneficial in patients with a history of AF undergoing coronary bypass surgery (CABG) for the
      concomitant treatment of AF. The investigators aim to establish the effectiveness of
      incorporating epicardial pulmonary vein isolation into elective cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inclusion rate insufficiënt
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of atrial fibrillation</measure>
    <time_frame>one year</time_frame>
    <description>The percentage of patients without a recurrence of AF, without antiarrhythmic drugs (AADs), within a follow-up period of at least 12 months after a stabilisation period of 90 days after the initial procedure. An episode of AF is defined as an episode of at least 30 seconds duration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>One year</time_frame>
    <description>Secondary objectives include the duration of hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epicardial pulmonary vein isolation</intervention_name>
    <description>After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.</description>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
    <other_name>Medtronic Cardioblate BP2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years of age

          -  EHRA class ≤ 2

          -  Documented history of paroxysmal, persistent, longstanding persistent or
             newly-diagnosed AF prior to admittance for cardiac surgery

          -  Patients will have elective coronary surgery planned Able of providing informed
             consent

        Exclusion Criteria:

          -  Patients ≥70 years of age

          -  Pregnancy Patients with contraindications for oral anticoagulant agents

          -  Patients undergoing emergency operation

          -  Patients undergoing concomitant valve replacement

          -  Severely enlarged LA (&gt;50 mm) on echocardiography

          -  Prior AF ablation or AF surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcoen Scholten, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medisch Spectrum Twente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medisch Spectrum Twente</investigator_affiliation>
    <investigator_full_name>B. Oude Velthuis</investigator_full_name>
    <investigator_title>B. Oude Velthuis MD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

